Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-22 00:00:00 ET · period of report 2023-02-17 · accession 0001209191-23-011701 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-22 | 2023-02-17 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $292.85 | -3,750 | 56.0K | -6% | -$1.10M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-17 | F | D | 3,750 | $292.85 | 55,984 | D | — | — |